The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Improvements over time in elderly patients with AML treated with alloSCT: an EBMT Registry study
Ali Bazarbachi, MD, PhD, American University of Beirut, Beirut, Lebanon, shares the findings of a study evaluating the outcomes of allogeneic stem cell transplantation (alloSCT) in older patients with acute myeloid leukemia (AML). Using a large dataset from the EBMT Registry, this study investigated patients with AML who were allografted using a matched sibling donor (MSD), unrelated donor (UD), or haploidentical donor, between the years 2000 and 2021. Results demonstrated that there was an impressive improvement over time in post-transplant outcomes for older patients with AML, with a decrease in cumulative incidence of relapse (CIR) and an increase in leukemia-free survival (LFS), overall survival (OS), as well as graft-versus-host disease (GvHD)-free, relapse-free survival (GRFS). These large-scale, real-world data can serve as a benchmark for future studies. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
